To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of melanoma with high risk of recurrence.
 
Status In progress
Process STA pre-2018
ID number 1266

Provisional Schedule

Expected publication 20 February 2019

Project Team

Project lead Gemma Barnacle

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Association of Dermatologists
  British Association of Skin Cancer Specialist Nurses
  Cancer Research UK
  Melanoma Focus
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies None
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
18 September 2018 Committee meeting: 1
16 April 2018 Invitation to participate
02 October 2017 - 31 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
28 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance